Viracept

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
10-06-2014
Tabia za bidhaa Tabia za bidhaa (SPC)
10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
10-06-2014

Viambatanisho vya kazi:

nelfinavir

Inapatikana kutoka:

Roche Registration Ltd.

ATC kanuni:

J05AE04

INN (Jina la Kimataifa):

nelfinavir

Kundi la matibabu:

Antivirals for systemic use

Eneo la matibabu:

HIV Infections

Matibabu dalili:

Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.

Bidhaa muhtasari:

Revision: 25

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

1998-01-22

Taarifa za kipeperushi

                                58
B. PACKAGE LEAFLET
Medicinal product no longer authorised
59
PACKAGE LEAFLET: INFORMATION FOR THE USER
VIRACEPT 50 MG/G ORAL POWDER
Nelfinavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
•
If any of the side effects become serious or troublesome, or if you
notice any side effects not
listed in this leaflet, please tell your doctor or pharmacist.
IN THIS LEAFLET:
1.
What Viracept is and what it is used for
2.
Before you take Viracept
3.
How to take Viracept
4.
Possible side effects
5.
How to store Viracept
6.
Further information
1.
WHAT VIRACEPT IS AND WHAT IT IS USED FOR
WHAT VIRACEPT IS
Viracept contains a medicine called nelfinavir, which is a ‘protease
inhibitor’. This belongs to a group
of medicines called ‘anti-retrovirals’.
WHAT VIRACEPT IS USED FOR
Viracept is used with other ‘anti-retroviral’ medicines to:
•
Work against the Human Immunodeficiency Virus (HIV). It helps to
reduce the number of HIV
particles in your blood.
•
Increase the number of some cells in your blood that help fight
infection. These are called CD4
white blood cells. They are particularly reduced in numbers when you
have HIV infection. This
can lead to an increased risk of many types of infections.
Viracept is not a cure for HIV infection. You may continue to get
infections or other illnesses due to
your HIV. Treatment with Viracept does not stop you giving HIV to
others through contact with blood
or sexual contact. Therefore you must keep taking appropriate
precautions to avoid giving the virus to
others when you are taking Viracept.
2.
BEFORE YOU TAKE VIRACEPT
DO NOT TAKE VIRACEPT IF:
•
You are allergic to nelfinavir or to any of the other ingredients
(listed in Section 6 ‘Further
information’).
•
You are taking any o
                                
                                Soma hati kamili

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
VIRACEPT 50 mg/g oral powder.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
The bottle contains 144 g of oral powder. Each gram of oral powder
contains nelfinavir mesilate
corresponding to 50 mg of nelfinavir.
Excipients
:
-
Contains sucrose palmitate: 10.0 mg per gram of oral powder. 10.0 mg
of sucrose palmitate,
which is an ester, theoretically corresponds to maximally 5.9 mg of
sucrose when fully
hydrolysed.
-
Contains aspartame (E951): 20.0 mg of aspartame per gram of oral
powder.
-
Contains potassium: 50.0 mg of dibasic potassium phosphate
corresponding to 22.5 mg of
potassium per gram of oral powder.
See section 4.4
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral powder.
White to off-white amorphous powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
VIRACEPT is indicated in antiretroviral combination treatment of human
immunodeficiency virus
(HIV-1) infected adults, adolescents and children of 3 years of age
and older.
In protease inhibitor (PI) experienced patients the choice of
nelfinavir should be based on individual
viral resistance testing and treatment history.
See section 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Therapy with VIRACEPT should be initiated by a physician experienced
in the management of HIV
infection.
VIRACEPT is administered orally and should always be ingested with
food (see section 5.2).
_Patients older than 13 years:_
VIRACEPT 250 mg tablets are recommended for adults and older
children (see Summary of Product Characteristics for VIRACEPT 250 mg
tablets). The recommended
dose of VIRACEPT 50 mg/g oral powder is 1250 MG TWICE A DAY (BID) OR
750 MG THREE TIMES A DAY
(TID), for patients unable to take tablets. All patients older than 13
years should take EITHER 5 level
scoops of the blue 5 gram spoon twice daily OR 3 level scoops of the
blue 5 gram spoon three times
daily. The efficacy of the BID (twice daily) regimen has been
ev
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi nelfinavir

nelfinavir

ATC kanuni J05AE04

J05AE04

Mzalishaji au wazalishaji wadogowadogo Roche Registration Ltd.

Roche Registration Ltd.

INN (Jina la Kimataifa) nelfinavir

nelfinavir

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kibulgaria 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kihispania 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kicheki 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kidenmaki 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kijerumani 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiestonia 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kigiriki 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kifaransa 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiitaliano 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kilatvia 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kilithuania 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kihungari 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kimalta 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiholanzi 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kipolandi 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kireno 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiromania 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kislovakia 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kislovenia 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kifinlandi 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiswidi 10-06-2014
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kinorwe 10-06-2014
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 10-06-2014
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 10-06-2014

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Viracept nelfinavir

Viracept nelfinavir

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Viracept